Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and selling innovative therapies for significant unmet medical needs. The company uses technologies like genetics and genomics in drug discovery, clinical trials, and product positioning. Vanda's current commercial portfolio includes four products. Fanapt® treats acute manic or mixed episodes associated with bipolar I disorder and schizophrenia. HETLIOZ® treats Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis syndrome (SMS); it was the first product approved by the United States Food and Drug Administration (FDA) for both Non-24 and SMS patients. PONVORY® treats relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. NEREUS™ prevents vomiting induced by motion. Vanda also has several drugs and additional indications for existing products in development. These include a long-acting injectable formulation of Fanapt® for schizophrenia and hypertension; Bysanti™ for acute manic or mixed episodes associated with bipolar I disorder, schizophrenia, and major depressive disorder (MDD); HETLIOZ® for jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD), and pediatric Non-24; PONVORY® for psoriasis and ulcerative colitis; NEREUS™ for preventing vomiting induced by GLP-1 receptor agonists, and treating gastroparesis and atopic dermatitis; Imsidolimab for generalized pustular psoriasis (GPP); and VTR-297, a small molecule histone deacetylase (HDAC) inhibitor.